Gimeno-Valiente Francisco, López-Rodas Gerardo, Castillo Josefa, Franco Luis
Cancer Evolution and Genome Instability Laboratory, University College London Cancer Institute, London WC1E 6DD, UK.
Department of Oncology, Institute of Health Research INCLIVA, 46010 Valencia, Spain.
Cancers (Basel). 2024 Jun 1;16(11):2123. doi: 10.3390/cancers16112123.
Cancer driver genes are either oncogenes or tumour suppressor genes that are classically activated or inactivated, respectively, by driver mutations. Alternative splicing-which produces various mature mRNAs and, eventually, protein variants from a single gene-may also result in driving neoplastic transformation because of the different and often opposed functions of the variants of driver genes. The present review analyses the different alternative splicing events that result in driving neoplastic transformation, with an emphasis on their molecular mechanisms. To do this, we collected a list of 568 gene drivers of cancer and revised the literature to select those involved in the alternative splicing of other genes as well as those in which its pre-mRNA is subject to alternative splicing, with the result, in both cases, of producing an oncogenic isoform. Thirty-one genes fall into the first category, which includes splicing factors and components of the spliceosome and splicing regulators. In the second category, namely that comprising driver genes in which alternative splicing produces the oncogenic isoform, 168 genes were found. Then, we grouped them according to the molecular mechanisms responsible for alternative splicing yielding oncogenic isoforms, namely, mutations in cis splicing-determining elements, other causes involving non-mutated cis elements, changes in splicing factors, and epigenetic and chromatin-related changes. The data given in the present review substantiate the idea that aberrant splicing may regulate the activation of proto-oncogenes or inactivation of tumour suppressor genes and details on the mechanisms involved are given for more than 40 driver genes.
癌症驱动基因要么是原癌基因,要么是肿瘤抑制基因,传统上分别通过驱动突变被激活或失活。可变剪接——从单个基因产生各种成熟mRNA,并最终产生蛋白质变体——也可能由于驱动基因变体的不同且通常相反的功能而导致肿瘤转化。本综述分析了导致肿瘤转化的不同可变剪接事件,重点关注其分子机制。为此,我们收集了一份包含568个癌症基因驱动因子的列表,并查阅文献,以选择那些参与其他基因可变剪接的基因,以及那些其前体mRNA经历可变剪接的基因,结果在这两种情况下都会产生致癌异构体。31个基因属于第一类,包括剪接因子、剪接体成分和剪接调节因子。在第二类中,即包括可变剪接产生致癌异构体的驱动基因,共发现168个基因。然后,我们根据导致可变剪接产生致癌异构体的分子机制对它们进行分组,即顺式剪接决定元件中的突变、涉及未突变顺式元件的其他原因、剪接因子的变化以及表观遗传和染色质相关变化。本综述给出的数据证实了异常剪接可能调节原癌基因激活或肿瘤抑制基因失活的观点,并给出了40多个驱动基因所涉及机制的详细信息。